Pediatrix Medical Group, Inc. (MD)
(Delayed Data from NYSE)
$16.08 USD
+0.72 (4.69%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $16.06 -0.02 (-0.12%) 7:58 PM ET
1-Strong Buy of 5 1
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.08 USD
+0.72 (4.69%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $16.06 -0.02 (-0.12%) 7:58 PM ET
1-Strong Buy of 5 1
A Value A Growth C Momentum A VGM
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pediatrix Medical Group (MD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 18.92% and 2.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Pediatrix Medical Up 45.8% in 3 Months: Is it Too Late to Jump In?
by Zacks Equity Research
MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.
Pediatrix Medical Group (MD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Why Is Pediatrix Medical Group (MD) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix Medical Group (MD) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Pediatrix Medical Group (MD) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
All You Need to Know About Pediatrix Medical Group (MD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Pediatrix Medical Group (MD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here Is Why Bargain Hunters Would Love Fast-paced Mover Pediatrix Medical Group (MD)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Pediatrix Medical Group (MD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
MD or RVTY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. RVTY: Which Stock Is the Better Value Option?
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.
Pediatrix Medical Group (MD) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 9.68% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Pediatrix Medical (MD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.
Implied Volatility Surging for Pediatrix Medical (MD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pediatrix Medical (MD) stock based on the movements in the options market lately.
Why Is Pediatrix Medical Group (MD) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees
by Zacks Equity Research
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.
Compared to Estimates, Pediatrix Medical Group (MD) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Pediatrix Medical Group (MD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Life Time Group Holdings, Inc. (LTH) Q1 Earnings Miss Estimates
by Zacks Equity Research
Life Time Group Holdings (LTH) delivered earnings and revenue surprises of -6.25% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ICON (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix Medical Group, Inc. (MD) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pediatrix Medical Group, Inc. (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes
by Zacks Equity Research
Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.
Pediatrix Medical Group (MD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Pediatrix Medical Group (MD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.